Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis
Liver International · 2026-11 · 46 (11)
DOI: 10.1111/liv.70933 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Liver International, online erschienen am 21.10.2026. Verfasst von Jinxia Liu und 54 weiteren Autor:innen. Beteiligte Einrichtung: Liver Failure Group, UCL Institute for Liver and Digestive Health, London, UK. Hauptthemen laut MEDLINE: Liver Cirrhosis, Gastrointestinal Microbiome. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Jinxia Liu, Rajiv Jalan.
Abstract (Originalsprache)
Background & Aims YAQ001 is a novel, non‐absorbable, gut‐restricted, multiporous, carbon bead adsorbent. Pre‐clinical studies and a clinical trial suggested its therapeutic potential and safety in patients with cirrhosis. This substudy aimed to explore the effects of YAQ001 on the gut microbiome and their exploratory association with biomarkers of gut permeability and systemic inflammation.
Methods
Twenty‐eight‐patients with cirrhosis were randomized (double‐blind) to receive YAQ001 (4 g once daily) or placebo. Gut microbiome and biomarkers of inflammation and gut permeability were assessed at baseline, after 4 and 12 weeks. Changes in biomarkers and relationship with microbiome composition and gene profiling were assessed. The effect of YAQ001 on Klebsiella pneumoniae biofilms was assessed in vitro.
Results
Overall alpha and beta diversity remained unaltered. YAQ001 increased the abundance of bacteria associated with improved gut health such as Adlercreutzia equolifaciens , a bacterium commonly depleted in liver disease, and decreased the abundance of bacteria associated with infections and poor outcomes such as Klebsiella pneumonia , and Streptococcus mutans . YAQ001 impacted positively on virulence factors such as siderophores, fimbriae structures, and lipopolysaccharides that are associated with inflammation and invasion. Antibiotic resistance genes decreased significantly in the YAQ001 group. These changes were associated with a reduction in markers of gut permeability and systemic inflammation. YAQ001 prevented K. pneumoniae biofilms in vitro.
Conclusion
YAQ001 was associated with favourable compositional shifts and trends towards reduced virulence‐related gene signatures in the gut microbiome, alongside trends towards improved inflammatory biomarkers. The in vitro anti‐biofilm effect of YAQ001 warrants further mechanistic investigation. The findings position YAQ001 as a potential microbiome therapeutic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Failure Group, UCL Institute for Liver and Digestive Health, London, UK.
- Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong, China.
- Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, UK.
- Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain.
- Division of Medicine, Department of Renal Medicine, University College London, London, UK.
- Department of Engineering Science, University of Oxford, Oxford, UK.
ORCID-Profile: Jinxia Liu, Jane Macnaughtan, Yi Jin, Ainhoa Ferret-Miñana, Nicholas Yuen, Javier Ramón-Azcón, Theo Portlock, Alexandra Phillips, Francesco De Chiara, Tom Baldwin, Cesar Jimenez, Giacomo Zaccherini, Miguel Rodriguez-Gandia, Jude A Oben, Jia V Li, Elsa Sola, Simon Eaton, Daniel Green, Lindsey Ann Edwards, I Jane Cox, Helena Cortez-Pinto, Francois Durand, Paolo Caraceni, Rajeshwar P Mookerjee, Susan Sandeman, Gautam Mehta, Julian R Marchesi, Agustin Albillos, Jennifer L Rohn, Saeed Shoaie, Rajiv Jalan
Förderung
- Wellcome Trust
- Jinxia Liu
- Rajiv Jalan
Zitieren
APA
Liu, J., Garcia-Guevara, F., Macnaughtan, J., Jin, Y., Ferret-Miñana, A., Clasen, F., Yuen, N., Maset, R. G., Ramón-Azcón, J., Kerbert, A. J. C., Portlock, T., Martinez, J., Habtesion, A., Phillips, A., De Chiara, F., Ingavle, G., Baldwin, T., Jimenez, C., Zaccherini, G., …, & Jalan, R. (2026). Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis. Liver International, 46(11). https://doi.org/10.1111/liv.70933
Vancouver
Liu J, Garcia-Guevara F, Macnaughtan J, Jin Y, Ferret-Miñana A, Clasen F, et al. Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis. Liver International. 2026;46(11). doi:10.1111/liv.70933
BibTeX
@article{Liu2026,
author = {Liu, Jinxia and Garcia-Guevara, Fernando and Macnaughtan, Jane and Jin, Yi and Ferret-Miñana, Ainhoa and Clasen, Frederick and Yuen, Nicholas and Maset, Ramón Garcia and Ramón-Azcón, Javier and Kerbert, Annarein J C and Portlock, Theo and Martinez, Javier and Habtesion, Abeba and Phillips, Alexandra and De Chiara, Francesco and Ingavle, Ganesh and Baldwin, Tom and Jimenez, Cesar and Zaccherini, Giacomo and Husi, Katherine and Rodriguez-Gandia, Miguel and Cordero-Sanchez, Paul and Soeda, Junpei and Oben, Jude A and Church, Karen and Li, Jia V and Jalan, Aarti and Juanola, Adria and Sola, Elsa and Eaton, Simon and Morgan, Carrie and Avery, Thomas and Kowalski, Michal and Green, Daniel and Gander, Amir and Edwards, Lindsey Ann and Cox, I Jane and Cortez-Pinto, Helena and Wiest, Reiner and Durand, Francois and Caraceni, Paolo and Elosua, Roberto and Vila, Joan and Pavesi, Marco and Arroyo, Vicente and Davies, Nathan and Mookerjee, Rajeshwar P and Sandeman, Susan and Mehta, Gautam and Marchesi, Julian R and Albillos, Agustin and Rohn, Jennifer L and Andreola, Fausto and Shoaie, Saeed and Jalan, Rajiv},
title = {Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis},
journal = {Liver International},
year = {2026},
volume = {46},
number = {11},
doi = {10.1111/liv.70933}
}
EUVIMED